Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Of Japan To Develop ER Painkiller Patch Solely For Japan

This article was originally published in PharmAsia News

Executive Summary

Japan's Janssen Pharmaceutical, a subsidiary of U.S.-based Johnson & Johnson, has applied to develop an extended-release painkiller developed for the Japanese market. Janssen's Durotep (fentanyl) is a one-day analgesic patch, which the firm hopes to be able to begin marketing next year. The patch is available as a three-day treatment, but patients complained they needed to change the patch so they could bathe daily. Janssen used the technology of a J&J joint venture with biotech Alza to develop an extended-release version. (Click here for more - a subscription may be required

You may also be interested in...



Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Finance Watch: Poseida, Nkarta And Inventiva Are July’s First Biopharma IPOs

Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel